Navigation Links
Therapure Biopharma Inc. Announces Delivery of its First Commercial-Scale Lyophilizer
Date:11/8/2009

Freeze-drying of biopharmaceuticals to be available at the Company’s Mississauga, Ontario facility.

Toronto, ON (PRWEB) November 8, 2009 -- Thomas Wellner, President and CEO of Therapure Biopharma Inc. today announced that the Company has taken delivery of a commercial scale pharmaceutical grade freeze dryer and expects to make commercial scale freeze drying (lyophilization) available for contract manufacturing of biopharmaceuticals early in 2010.

Lyophilization is used to convert biopharmaceuticals that are manufactured in an unstable liquid format into a stable, dry powder that can be reconstituted to a liquid format for administration to patients. Lyophilized forms of these life-saving products are more easily handled and stable than their liquid forms and therefore lyophilization is commonly used in the manufacture of these products.

“Commercial scale lyophilization is not readily available in Canada,” said Thomas Wellner. “The addition of a commercial-scale lyophilizer to the clinical scale capability Therapure Biopharma has now will significantly enhance the value we will bring to Therapure clients.”

Installation of the lyophilizer began last week and is expected to be completed in December. Following the installation, the Company will complete the extensive validation process required to achieve current Good Manufacturing Practices (cGMP) status. Therapure Biopharma will begin offering commercial-scale lyophilization services from its Health Canada commercially licensed plant early in 2010.

About Therapure Biopharma:
Therapure Biopharma Inc. is an integrated biopharmaceutical company that develops, manufactures, purifies, and packages therapeutic proteins. As a contract development and manufacturing organization (CDMO) Therapure Biopharma applies scientific, manufacturing, and downstream purification expertise with an intimate understanding of advanced biology, complex proteins, and regulatory processes to develop effective and innovative solutions to advance products from discovery to market.

For more information, please visit: www.therapurebio.com

Media Contacts:
Thomas Wellner, President and CEO
Therapure Biopharma Inc.
+1 905-286-6204

# # #

Read the full story at http://www.prweb.com/releases/2009/11/prweb3172054.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved

Related medicine news :

1. Therapure Biopharma Inc. and LFB Biotechnologies Announce Development Services Contract for New Therapeutic Protein
2. Surviving Healthcare Reform: How Biopharma Companies Can Come Out on Top
3. aTyr Pharma to Present at Japan Biopharma Partnering Conference
4. Keryx Biopharmaceuticals, Inc. to Hold Investor/Analyst Day Tomorrow
5. DOR BioPharma Announces $9.4 Million NIH Grant Award to Develop Thermostable and Rapidly Acting Vaccines
6. PDL BioPharma Announces Conversion Rate Adjustment for Its 2.75% Convertible Subordinated Notes Due August 16, 2023
7. Keryx Biopharmaceuticals Receives Orphan-Drug Designation for KRX-0401 (Perifosine) for the Treatment of Multiple Myeloma
8. UK's Newcastle University Introduces First-Ever Biopharmaceutical Engineering Doctorate Program
9. PDL BioPharma to Present at BioCentury Newsmakers Conference on September 16, 2009
10. Frost & Sullivan Global Heart Health Ingredients Excellence in Financial & Risk Management Award Conferred on Pronova BioPharma
11. Keryx Biopharmaceuticals, Inc. To Present at the Rodman & Renshaw Annual Global Investment Conference and To Hold Investor/Analyst Day
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... ... March 27, 2017 , ... According to the American Cancer Society , ... more than 95%. Once the cancer spreads to other organs, bones, or lymph nodes, ... how to avoid this latter group, tune in to Lifestyle Magazine on ...
(Date:3/27/2017)... ... March 27, 2017 , ... Sodium determination ... are complicated and require expert user knowledge. In a live webinar on April ... the simplified, yet highly accurate, determination of sodium. , It has long been ...
(Date:3/27/2017)... Irvine, CA (PRWEB) , ... March 27, 2017 ... ... company has entered a settlement agreement to resolve the pending litigation between itself ... Court for the District of Utah). , “I am thrilled to announce that ...
(Date:3/27/2017)... (PRWEB) , ... March 27, 2017 , ... ... deaths soared 167%,(1) with opioids alone responsible for over 33,000 of the 52,404 ... has sponsored Assembly Bill (AB) 1512, which proposes a tax on prescription opioids ...
(Date:3/27/2017)... , ... March 27, 2017 , ... Harris Communications, Inc., ... hearing, is bringing its latest products to the Deaf Seniors of America Conference, April ... the opportunity to meet with knowledgeable ASL friendly staff from Harris Communications and to ...
Breaking Medicine News(10 mins):
(Date:3/24/2017)... DUBLIN , Mar. 24, 2017 Research and ... (IPF) Pipeline Analysis, 2016" report to their offering. ... The IPF pipeline is very strong with ... Corporation, Merck & Co., Inc., Biogen and Sanofi are involved in the ... candidates, of which one is in Phase III stage, 15 are in ...
(Date:3/24/2017)... Research and Markets has announced the addition of the "Microplate Instrumentation ... ... comprehensive analytics for the US, Canada , ... , Latin America , and Rest of World. Annual ... a six-year historic analysis is provided for these markets. Market data and ...
(Date:3/24/2017)... 23, 2017  Provectus Biopharmaceuticals, Inc. (OTCQB: PVCT, ... clinical-stage oncology and dermatology biopharmaceutical company, today disclosed ... Term Sheet (the "Definitive Financing") it entered into ... Company,s stockholders, who are referred to in the ... 8-K filed with the Securities and Exchange Commission. ...
Breaking Medicine Technology: